SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.

Autor:	Cheng SM; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; These authors contributed equally to the research., Mok CKP; These authors contributed equally to the research.; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Chan KC; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Ng SS; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Lam BH; Department of Pathology, North Lantau Hospital, Hong Kong SAR, China., Luk LL; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Ko FW; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Chen C; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Yiu K; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Li JK; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Chan KK; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Tsang LC; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Poon LL; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Centre for Immunology and Infection, Hong Kong Science Park, Shatin, Hong Kong SAR, China., Hui DS; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.; Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China., Peiris M; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Centre for Immunology and Infection, Hong Kong Science Park, Shatin, Hong Kong SAR, China.
Jazyk:	angličtina
Zdroj:	Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 May; Vol. 27 (18).
DOI:	10.2807/1560-7917.ES.2022.27.18.2200178
Abstrakt:	BackgroundOmicron subvariant BA.2 circulation is rapidly increasing globally.AimWe evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants.MethodsUsing 50% plaque reduction neutralisation tests (PRNT 50 ), we assessed neutralising antibody titres to BA.2, wild type (WT) SARS-CoV-2 and other variants in Comirnaty or CoronaVac vaccinees, with or without prior WT-SARS-CoV-2 infection. Titres were also measured for non-vaccinees convalescing from a WT-SARS-CoV-2 infection. Neutralising antibodies in BA.2 and BA.1 breakthrough infections and in BA.2 infections affecting non-vaccinees were additionally studied.ResultsIn vaccinees or prior WT-SARS-CoV-2-infected people, BA.2 and BA.1 PRNT 50 titres were comparable but significantly (p < 10 - 5) lower than WT. In each group of 20 vaccinees with (i) three-doses of Comirnaty, (ii) two CoronaVac followed by one Comirnaty dose, or (iii) one dose of either vaccine after a WT-SARS-CoV-2 infection, ≥ 19 individuals developed detectable (PRNT 50 titre ≥ 10) antibodies to BA.2, while only 15 of 20 vaccinated with three doses of CoronaVac did. Comirnaty vaccination elicited higher titres to BA.2 than CoronaVac. In people convalescing from a WT-SARS-CoV-2 infection, a single vaccine dose induced higher BA.2 titres than three Comirnaty (p = 0.02) or CoronaVac (p = 0.00001) doses in infection-naïve individuals. BA.2 infections in previously uninfected and unvaccinated individuals elicited low (PRNT 50 titre ≤ 80) responses with little cross-neutralisation of other variants. However, vaccinees with BA.1 or BA.2 breakthrough infections had broad cross-neutralising antibodies to WT viruses, and BA.1, BA.2, Beta and Delta variants.ConclusionsExisting vaccines can be of help against the BA.2 subvariant.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu